In the KEYNOTE-028 trial, pembrolizumab monotherapy in PD-L1-positive, HR+/HER2− breast cancer patients yielded an objective response rate (ORR) of only 12%, suggesting limited single-agent activity in this subtype [21]. Here, CD274 is linked to breast carcinoma.